NCT06314373Recruiting
A Study for HSK39775 in Participants With Solid Tumors
A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies
Xizang Haisco Pharmaceutical Co., LtdPhase 1/2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Advanced Solid Tumors
- Drug/Device/Intervention
- HSK39775 Monotherapy
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Xizang Haisco Pharmaceutical Co., Ltd
- Funder
- Haisco Pharmaceutical Group Co., Ltd.
- Location
- Shanghai, China
Timeline & enrollment
- Phase
- Phase 1/2
- Start date
- Mar 07, 2024
- End date
- Sep 01, 2028
- Enrollment
- 243 participants
Primary outcome
AE/SAE,DLT,MTD/MAD
Summary
This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer
 activity in patients with advanced solid tumors.
ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06314373
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06314373 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Xizang Haisco Pharmaceutical Co., Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 243 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.